Hu Xueliang | Treatment for Infectious Diseases | Best Researcher Award

Posted on by Infectious

Ms. Hu Xueliang | Treatment for Infectious Diseases | Best Researcher Award

Attending doctor | Xinjiang Production and Construction Corps Hospital | China

Dr. Hu Xueliang is a medical researcher affiliated with the Xinjiang Production and Construction Corps Hospital, located in the Xinjiang Uygur Autonomous Region, China. He has developed a multidisciplinary academic foundation built upon rigorous medical education and clinical research training, which fuels his pursuit of excellence in scientific inquiry. His educational background includes advanced studies in clinical medicine and infectious diseases, with specialized exposure to epidemiology, antimicrobial resistance, and translational healthcare practices. Professionally, Dr. Hu has accumulated significant experience working in medical and hospital-based research environments where he has contributed to evidence-based clinical investigations, research collaborations, and the analysis of disease patterns. His research interests span infectious diseases, public health, immunopathology, epidemiological modeling, and antimicrobial stewardship, focusing on the development of innovative strategies for the prevention and control of emerging infectious threats. Dr. Hu demonstrates strong research skills in data collection, statistical evaluation, clinical interpretation, and collaborative project leadership, reflecting a growing engagement in translational research that bridges clinical medicine and public health outcomes. Throughout his developing career, he has earned recognition for his dedication and academic integrity, receiving institutional appreciation and professional commendations for research excellence and medical service. His academic achievements and contributions position him as an emerging scholar within the global medical research community, demonstrating both promise and perseverance. Dr. Hu continues to pursue knowledge dissemination through publications, scientific participation, and health advocacy aimed at improving patient outcomes and public safety. He envisions building a strong research portfolio in infectious disease diagnostics and evidence-based medicine while strengthening global collaboration in health sciences.his current publication metrics indicate 0 Citations  and 1 Document with 0 h-index, reflecting his early-career status and future potential for academic growth.

Profiles : Scopus 

Featured Publications

Hu, X., Guo, X., Sha, J., Dou, Y., Ma, H., Li, H., & Xu, Y. (2025). Analysis of the efficacy of photodynamic therapy in treating cervical lesions and HPV infections and its influencing factors. Photodiagnosis and Photodynamic Therapy, 55, 104786.

Sanaz Ahmadi | Diagnosis of Infectious Diseases | Best Researcher Award

Posted on by Infectious

Dr. Sanaz Ahmadi | Diagnosis of Infectious Diseases | Best Researcher Award

Researcher | Academic Center for Education, Culture and Research | Iran

Dr. Sanaz Ahmadi Ghezeldasht is a distinguished researcher and molecular biologist at the Molecular Biology Section, Central Laboratory ACECR, Mashhad, Iran, specializing in medical immunology, molecular virology, and infectious diseases. She holds a Ph.D. in Medical Immunology from Mashhad University of Medical Sciences, an M.Sc. in Animal Physiology from Payam-e-Noor University of Isfahan, and a B.Sc. in Biology from Ferdowsi University of Mashhad. Dr. Ghezeldasht has served as the Supervisor of the Molecular Biology Center at Jahad Daneshgahi Mashhad, contributing to several national and international research projects focused on HTLV-1 pathogenesis, viral immunology, and host-virus interactions. Her prolific research portfolio encompasses numerous peer-reviewed publications in high-impact journals such as Reviews in Medical Virology, Journal of NeuroVirology, and Applied Biochemistry and Biotechnology, highlighting novel insights into viral oncogenesis, molecular diagnostics, and therapeutic development. A dedicated academic leader, she has organized and contributed to multiple scientific congresses and health monitoring initiatives. Dr. Ghezeldasht’s expertise extends to genetic engineering, bioinformatics, PCR technologies, and cell culture, complemented by certifications in English proficiency and advanced computer literacy. She is an active member of the HTLV-I Foundation and the Research Center for HIV/AIDS, HTLV, and Viral Hepatitis at ACECR, reflecting her enduring commitment to advancing molecular medicine and public health. Her scholarly impact is reflected by 409 citations across 26 publications with an h-index of 10.

Profiles: Scopus | ORCID

Featured Publication

1. Shafaei, A., Talebi, K., Zarean, M., Mosavat, A., Khajedaluee, A. R., Afzalaghaee, M., Shamsian, S. A. A., & Ghezeldasht, S. A. (2025). Intestinal parasitic infections, eosinophilia, and Th1/Th2 immune profiles in haemodialysis patients. Parasite Immunology.

2. Rahimzada, M., Nahavandi, M., Saffari, M., Shafaei, A., Mosavat, A., Ghezeldasht, S. A., Ariaee, N., Valizadeh, N., Rahimi, H., Rezaee, S. A., et al. (2023). Gene expression study of host-human T-cell leukaemia virus type 1 (HTLV-1) interactions: adult T-cell leukaemia/lymphoma (ATLL). Molecular Biology Reports, 50(9).

3. Yousefpoor, N., Mahdavian, M., Pourbagher, Z., Ghezeldasht, S. A., Mosavat, A., Ziaee, M., Bahreini, M., Soleimanpour, S., Sharifmoghadam, M. R., Valizadeh, N., et al. (2023). Role of host immunity and HBx among inactive chronic hepatitis B patients in a highly endemic region. Microbial Pathogenesis, 180, 106170.

4. Ghezeldasht, S. A., Bidkhori, H. R., Miri, R., Baghban, A., Mosavat, A., & Rezaee, S. A. (2023). Momordica charantia phytoconstituents can inhibit human T-lymphotropic virus type-1 (HTLV-1) infectivity in vitro and in vivo. Journal of NeuroVirology, 29(4), 567–578.

Dr. Xiaotian Xu | Global Health | Best Researcher Award

Posted on by Infectious

Dr. Xiaotian Xu | Global Health | Best Researcher Award

Guilin Medical University | China.

Author Profile

Scopus

🎓Education

Assoc. Prof. Dr. Xiaotian Xu obtained his Ph.D. in Traditional Chinese Medicine from China Pharmaceutical University in 2017, building on his strong foundation with a B.Sc. in Traditional Chinese Medicine from the same institution in 2012. His academic journey has been dedicated to exploring the therapeutic potential of traditional medicine through modern scientific approaches.

💼Professional Experience

Assoc. Prof. Dr. Xiaotian Xu has been serving as an Associate Professor at the School of Pharmacy, Guilin Medical University since 2021, where he focuses on research and education in pharmaceutical sciences. Prior to this, he worked as a Lecturer at the same institution from 2017 to 2021, contributing to academic development and advancing research in traditional medicine and pharmacology.

📚Academic Contributions

Dr. Xu has published multiple high-impact research articles in Journal of Functional Foods, European Journal of Pharmaceutical Sciences, and Cell Death & Disease, focusing on anti-inflammatory compounds and cancer treatment.

🧑‍🔬Technical Skills 

Dr. Xiaotian Xu possesses extensive expertise in natural product extraction and analysis, utilizing advanced techniques to isolate bioactive compounds. His proficiency in molecular pharmacology and cell culture & bioassays enables him to investigate drug mechanisms at the cellular level. Additionally, he specializes in animal disease models for evaluating therapeutic efficacy and applies data analysis & bioinformatics to interpret complex biological data, driving innovative research in pharmaceutical sciences.

📚Teaching Experience

 Assoc. Prof. Dr. Xiaotian Xu is actively involved in teaching Pharmacology of Traditional Chinese Medicine, where he bridges classical knowledge with modern scientific principles. He also lectures on Drug Discovery and Development, guiding students through the processes of identifying and formulating new therapeutic agents. Additionally, he teaches Advanced Research Methods, equipping students with essential skills in experimental design, data analysis, and scientific writing to enhance their research capabilities.

🏆Awards and Honors

NSFC Grant Recipient (2024) for research on durian shell polysaccharides in inflammatory bowel disease

Chinese Patent Holder (2021) for a novel extraction method of p-hydroxybenzaldehyde

🔬Research Interests

Natural compounds in inflammatory disease treatment

Cancer stem cell suppression & ferroptosis

Pharmacological mechanisms of traditional medicine

📑Notable Publications 

“Deep learning-based discovery of compounds for blood pressure lowering effects”

Authors: Li, R.; Wu, T.; Xu, X.; Duan, X.; Wang, Y.
Year: 2025
Journal: Scientific Reports

“p-Hydroxy benzaldehyde, a phenolic compound from Nostoc commune, ameliorates DSS-induced colitis against oxidative stress via the Nrf2/HO-1/NQO-1/NF-κB/AP-1 pathway”

Authors: Liu, M.; Guan, G.; Wang, Y.; Duan, X.; Xu, X.
Year: 2024
Journal: Phytomedicine

“Passion fruit peel fermentation extract and its active component kaempferol alleviate constipation and hemorrhoids in mice by downregulating ESR1 and PI3K/Akt pathways”

Authors: Xu, X.; Li, X.; Wei, X.; Duan, X.; Wang, Y.
Year: 2024
Journal: Journal of Functional Foods

“Characteristics and Influence Factors of Pb(II) Adsorption by Graphene Oxide-Montmorillonite Composite”

Authors: Zhifang, Z.; Xiaotian, X.; Dongxia, L.; Jinlin, C.; Jiyi, Z.
Year: 2024
Journal: Chemistry and Biodiversity

“p-Hydroxy benzaldehyde attenuates intestinal epithelial barrier dysfunction caused by colitis via activating the HNF-1β/SLC26A3 pathway”

Authors: Liu, M.; Wang, Y.; Xu, X.; Zhu, Y.; Duan, X.
Year: 2024
Journal: Frontiers in Pharmacology